Prospects for the resistance to HIV protease inhibitors: Current drug design approaches and prespectives

Current Pharmaceutical Design

Volumn 11, Issue 24, 2005, Pages 3077-3090

  Burlet, Stéphane ^a   Pietrancosta, Nicolas ^a   Laras, Younes ^a   Garino, Cédrik ^a   Quéléver, Gilles ^a   Kraus, Jean Louis ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; 6 [2 (4 AMINOPHENYL)ETHYL] 3 (2 TERT BUTYL 4 HYDROXY 5 METHYLPHENYLTHIO) 5,6 DIHYDRO 4 HYDROXY 6 ISOPROPYL 2 PYRANONE; A 70450; ALUVIRAN; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ASPARTIC PROTEINASE INHIBITOR; ATAZANAVIR; BMS 234475; BRECANAVIR; DARUNAVIR; DPC 681; DPC 684; INDINAVIR; JE 2147; KNI 529; KNI 764; LASINAVIR; LIMONOID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LYCERNUIC ACID C; MOZENAVIR; NELFINAVIR; NOMILIN; PNU 140690E; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SM 319377; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS MUTATION; VIRUS RESISTANCE;

DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23844551491     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054864939     Document Type: Review

References (59)

1. Schmidt B. Aspartic proteases involved in Alzheimer's disease. Chembiochem 2003; 4: 366-378.
2. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-Cell decay in vivo. J Virol 2003; 77: 5037-5038.
3. Tomasselli AG, Heinrikson RL. Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim Biophys Acta-Protein Struct Molec Enzym 2000; 1477; 189-214.
4. Norbeck DW. Recent Advances in Antiretroviral Chemotherapy for Aids. Annu Rep Med Chem 1990; 25: 149-158.
5. Tomasselli AG, Sarcich JL, Barrett LJ, Reardon IM, Howe WJ, Evans DB, et al. Human-Immunodeficiency-Virus Type-1 Reverse-Transcriptase and Ribonuclease-H as Substrates of the Viral Protease. Protein Sci 1993; 2: 2167-2176.
6. Tomasselli AG, Heinrikson RL. Specificity of Retroviral Proteases - an Analysis of Viral and Nonviral Protein Substrates. Retroviral Proteases. Methods Enzymol 1994; 241: 279-301.
7. Kutilek VD, Sheeter DA, Elder JH, Torbett BE. Is Resistance Futile? Curr Drug Targets Infect Disord 2003; 3: 295-309.
8. Thaisrivongs S. HIV Protease Inhibitors. Annu Rep Med Chem 1994; 29: 133-144.
9. Swanstrom R, Eron J. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol Therapeut 2000; 86: 145-170.
10. Norbeck DW, Kempf K. J. HIV Protease Inhibitors. Annu Rep Med Chem 1991; 26: 141-150.
11. Pillay D, Taylor S, Richman DD. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol 2000; 10: 231-253.
12. Briones C, Perez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acq Immun Def Synd 2001; 26: 145-150.
13. Perez-Olmeda M, Rubio A, Puig T, Gomez-Cano M, Ruiz L, Leal M, et al. Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens. Antivir Ther 1999; 4: 179-181.
14. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: Effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188: 388-396.
15. Poulton MB, Sabin CA, Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequelae. Aids 2003; 17: 126-128.
16. Sham HL, Betebenner DA, Herrin T, Kumar G, Saldivar A, Vasavanonda S, et al. Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea synthesis and structure-activity relationships. Bioorg Med Chem Lett 2004; in press.
17. Bacheler LT, Jeffrey S, Logue K, Garber S, Diamond S, Kaltenbach R, et al. Resistance profiles of second generation HIV protease inhibitors DPC 681 and DPC 684. Antivir Ther 2001; 6 (S1), 5-6.
18. Raja A, Lebbos J. Atazanavir sulphate. Nat Rev Drug Discov 2003; 2: 857-858.
19. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, et al. BMS-232632; a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Ch 2000; 44: 2093-2099.
20. Lazdins JK, Mestan J, Goutte G, Walker MR, Bold G, Capraro HG, et al. In vitro effect of alpha(1)-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997; 175: 1063-1070.
21. Corbett AH, Kashuba AD. Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline. Curr Opin Investig Drugs 2002; 3: 384-390
22. Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, et al. Pharmacokinetics of GW433908; a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol 2002; 42: 887-898.
23. Miller JF, Furfine ES, Hanlon MH, Hazen RJ, Ray JA, Robinson L, et al. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorg Med Chem Lett 2004; 14: 959-963.
24. Kim EE, Baker CT, Dwyer MD, Murcko MA, Rao BG, Tung RD, et al. Crystal-Structure of HIV-1 Protease in Complex with Vx-478: a Potent and Orally Bioavailable Inhibitor of the Enzyme. J Am Chem Soc 1995; 117: 1181-1182.
25. Markland W, Rao BG, Parsons JD, Black J, Zuchowski L, Tisdale M, et al. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. J Virol 2000; 74: 7636-7641.
26. Pazhanisamy S, Stuver CM, Cullinan AB, Margolin N, Rao BG, Livingston DJ. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J Biol Chem 1996; 271: 17979-17985.
27. Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol 2002; 76: 1349-1358.
28. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram, T, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47: 3123-3129.
29. Arasteh K, Clumeck N, Pozniak A, Jaeger H, De Pauw M, Muller H, et al. Antiretroviral Activity, Resistance and Safety of TMC 114: a next generation HIV-protease inhibitor, in multiple PI-experienced patients. Abstract LB 16. Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. July 13-16: 2003; Paris, France.
30. Hoetelmans R, Van der Sandt I, De Pauw M, Struble K, Peeters M, Van der Geest R. TMC114: a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of Ritonavir in healthy volunteers. Abstract 549: 10th Conference on Retroviruses and Opportunistic Infections. February 10-14: 2003. Boston, MA, USA.
31. Velasquez-Campoy A, Freire E. Incorporating target heterogeneity in drug design. J Cell Biochem Suppl 2001; S37: 82-88.
32. Freire E. Designing drugs against heterogeneous targets. Nat Biotechnol 2002; 20: 15-16.
33. Ohtaka H, Velaquez-Campoy A, Xie D, Freire E. Overcoming drug resistance in HIV-1 chemotherapy: The binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants ofthe HIV-1 protease. Protein Sci 2002; 11: 1908-1916.
34. Mimoto T, Terashima K, Nojima S, Takaku H, Nakayama M, Shintani M, et al. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure. Bioorg Med Chem 2004; 12: 281-293.
35. Glenn MP, Pattenden LK, Reid RC, Tyssen DP, Tyndall JDA, Birch CJ, et al. beta-strand mimicking macrocyclic amino acids: Templates for protease inhibitors with antiviral activity. J Med Chem 2002; 45: 371-381.
36. March DR, Abbenante G, Bergman DA, Brinkworth RI, Wickramasinghe W, Begun J, et al. Substrate-based cyclic peptidomimetics of Phe-Ile-Val that inhibit HIV-1 protease using a novel enzyme-binding mode. J Am Chem Soc 1996; 118: 3375-3379.
37. Tyndall JDA, Reid RC, Tyssen DP, Jardine DK, Todd B, Passmore M, et al. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. J Med Chem 2000; 43: 3495-3504.
38. Fairlie DP, Tyndall JDA, Reid RC, Wong AK, Abbenante G, Scanlon MJ, et al. Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing. J Med Chem 2000; 43: 1271-1281.
39. Martin JL, Begun J, Schindeler A, Wickramasinghe WA, Alewood D, Alewood PF, et al. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Biochemistry 1999; 38: 7978-7988.
40. Bourinbaiar AS, Tan X, Nagorny R. Effect of the oral anticoagulant, warfarin, on HIV-1 replication and spread. Aids 1993; 7: 129-130.
41. Thaisrivongs S, Strohbach JW. Structure-based discovery of tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 1999; 51: 51-58.
42. Poppe SM, Slade DE, Chong KT, Hinshaw RR, Pagano PJ, Markowitz M, et al. Antiviral activity of the dihydro-pyrone PNU-140690; a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997; 41: 1058-1063.
43. Hagen SE, Domagala J, Gajda C, Lovdahl M, Tait BD, Wise E, et al. 4-hydroxy-5, 6-dihydropyrones as inhibitors of HIV protease: The effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. J Med Chem 2001; 44: 2319-2332.
44. Wild H, Hansen J, Lautz J.: IX International Conference on AIDS, June 7-11: 1993; Berlin, Germany.
45. Lam PYS, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, et al. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994; 263: 380-384.
46. Otto MJ, Garber S, Stack S, Winslow D. Reduced sensitivity to HIV PR inhibitors is associated with single amino acid substitutions in HIV-1 PR. Second International Workshop on HIV Drug Resistance. June 3-5: 1993; Noordwijk, Netherlands.
47. Hodge CN, Aldrich PE, Bacheler LT, Chang CH, Eyermann CJ, Garber S, et al. Improved cyclic urea inhibitors of the HIV-I protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol 1996; 3: 301-314.
48. Appelt K. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). October 17-20: 1993; New-Orleans, LA, USA.
49. Appelt K. Crystal structures of HIV-1 protease inhibitor complexes. Perspect Drug Discov Des 1993; 1: 23-48.
50. Debouck C, Gorniak JG, Strickler JE, Meek TD, Metcalf BW, Rosenberg M. Human immunodeficiency virus protease expressed in escherichia-coli exhibits autoprocessing and specific maturation of the Gag precursor. Proc Natl Acad Sci USA 1987; 84: 8903-8906.
51. Priem G, Rocheblave L, De Michelis C, Courcambeck J, Kraus JL. Synthesis and chemical reactivity of thiophenoxyphenylalanine bioisosteres, suitable synthons for the design of HIV protease inhibitors. J Chem Soc Perkin Trans 1 2000; 819-824.
52. Vlieghe P, Clerc T, Pannecouque C, Witvrouw M, De Clercq E, Salles JP, et al. New 3′-azido-3′-deoxythymidin-5′-yl O-(4-hydroxyalkyl or -alkenyl or -alkylepoxide) carbonate prodrugs: Synthesis and anti-HIV evaluation. J Med Chem 2001; 44: 3014-3021.
53. Kazmierski WM, Bevans P, Furfine E, Spaltenstein A. Yang HB. Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O -> N Acyloxy migration of P1 moiety. Bioorg Med Chem Lett 2003; 13: 2523-2526.
54. Battinelli L, Mengoni F, Lichtner M, Mazzanti G, Saija A, Mastroianni CM, et al. Effect of limonin and nomilin on HIV-1 replication on infected human mononuclear cells. Planta Med 2003; 69: 910-913.
55. Dash C, Kulkarni A, Dunn B, Rao M. Aspartic peptidase inhibitors: Implications in drug development. Crit Rev Biochem Mol Biol 2003; 38: 89-119.
56. Watkins T, Resch W, Irlbeck D, Swanstrom R. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2003; 47: 759-769.
57. Nair V. Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents. Curr Pharm Design 2003; 9(31): 2553-65.
58. Tozser J, Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr Pharm Design 2003; 9(22): 1803-15.
59. Vierling P, Greiner J. Prodrugs of HIV protease inhibitors. Curr Pharm Design 2003; 9(22): 1755-70.